FCG Investment Co Purchases 1,365 Shares of Gilead Sciences, Inc. $GILD

FCG Investment Co grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 21,931 shares of the biopharmaceutical company’s stock after purchasing an additional 1,365 shares during the period. Gilead Sciences makes up approximately 1.3% of FCG Investment Co’s holdings, making the stock its 18th largest position. FCG Investment Co’s holdings in Gilead Sciences were worth $2,431,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in GILD. Price T Rowe Associates Inc. MD lifted its holdings in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. Nuveen LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at $620,415,000. GAMMA Investing LLC boosted its stake in Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock valued at $285,761,000 after purchasing an additional 2,532,070 shares during the last quarter. Kingstone Capital Partners Texas LLC purchased a new stake in Gilead Sciences during the 2nd quarter valued at $238,083,000. Finally, Los Angeles Capital Management LLC boosted its stake in Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after purchasing an additional 2,040,261 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Down 2.4%

GILD opened at $110.99 on Friday. The firm has a 50-day simple moving average of $114.34 and a two-hundred day simple moving average of $109.96. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $137.72 billion, a PE ratio of 22.11, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. Gilead Sciences, Inc. has a 52 week low of $81.83 and a 52 week high of $121.83.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences’s dividend payout ratio is 62.95%.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at $18,120,661.35. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $9,390,030 in the last ninety days. 0.27% of the stock is owned by company insiders.

Analysts Set New Price Targets

GILD has been the topic of several recent analyst reports. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Friday, July 25th. Rothschild & Co Redburn boosted their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Finally, Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $117.17.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.